Skip to main content
WINLEVI® (clascoterone cream 1%) Logo
  • How It Works
  • Efficacy
  • Dosing & Safety
  • Resources
Get updates from WINLEVI
  • Important Safety Information
  • Prescribing Information
  • Patient Information
  • For Patients
Full Prescribing Information
View all View less

INDICATION

WINLEVI (clascoterone) cream 1% is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Local Irritation: Pruritus, burning, skin redness or peeling may be experienced with WINLEVI cream. If these effects occur, discontinue or reduce the frequency of application of WINLEVI cream.

Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with WINLEVI. In the PK trial, HPA axis suppression was observed in 5% of adult subjects and 9% of adolescent subjects at Day 14. All subjects returned to normal HPA axis function at follow-up 4 weeks after stopping treatment. Conditions which augment systemic absorption include use over large surface areas, prolonged use, and the use of occlusive dressings. Attempt to withdraw use if HPA axis suppression develops.

Pediatric patients may be more susceptible to systemic toxicity.

Hyperkalemia: Elevated potassium levels were observed in some subjects during the clinical trials. Shifts from normal to elevated potassium levels were observed in 5% of WINLEVI-treated subjects and 4% of vehicle-treated subjects.

ADVERSE REACTIONS

Most common adverse reactions occurring in 7% to 12% of patients are erythema/reddening, pruritus and scaling/dryness. Additionally, edema, stinging, and burning occurred in >3% of patients and were reported in a similar percentage of subjects treated with vehicle.

To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

For more details, please see full Prescribing Information and the Patient Information.

    SUN Dermatology Logo
    How It Works Efficacy Dosing & Safety Resources

    This site is intended for U.S. residents only. WINLEVI is a registered trademark of Cassiopea, S.p.A., used under exclusive license.
    All other trademarks are property of their respective owners.
    ©2022 Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc. All rights reserved.

    Sitemap Terms of Use Privacy Policy Contact